Plant Name: Callicarpa acuminata
Taxonomic Information:
Plant ID: NPO24937
Plant Latin Name: Callicarpa acuminata
Taxonomy Genus: Callicarpa
Taxonomy Family: Lamiaceae
Plant External Links:
NCBI TaxonomyDB:
461200
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CA2; CA7; CA4; CA14; | |
| PPARA; | |
| ALOX15; CBR1; | |
| XDH; | |
| FABP5; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | CBR1 | Carbonyl reductase [NADPH] 1 | P16152 | CHEMBL5586 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.665E-12 | 5.563E-08 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, XDH |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.616E-11 | 1.446E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.075E-10 | 2.602E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.346E-10 | 5.108E-07 | CA14, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.026E-09 | 1.718E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.517E-09 | 2.359E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.305E-08 | 2.390E-05 | CA14, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.254E-08 | 2.390E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 4.950E-08 | 4.686E-05 | ALOX15, CBR1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, XDH |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.322E-07 | 3.996E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.463E-06 | 8.609E-04 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.790E-06 | 9.743E-04 | CYP19A1, CYP1A1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.134E-06 | 1.106E-03 | CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.924E-06 | 1.447E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 7.305E-06 | 3.359E-03 | CYP1A2, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 1.363E-05 | 5.817E-03 | CYP1A1, CYP1A2 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 2.188E-05 | 8.989E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 2.444E-05 | 9.853E-03 | CBR1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.853E-18 | 1.334E-16 | CA12, CA1, CA2, CA4, CA7, CA6, CA9, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.708E-10 | 6.149E-09 | CYP2C9, CBR1, CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP2C19 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 2.702E-08 | 3.891E-07 | CBR1, GAA, ALOX15, AKR1B1, CYP2C19, CYP3A4, CYP19A1, HSD17B10, PTGS1, CYP2C9, CYP1A2, ALDH1A1, CYP1A1, XDH |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 4.826E-09 | 8.686E-08 | CYP2C9, CBR1, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 2.164E-09 | 5.193E-08 | CYP2C9, CYP1A2, ALOX15, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.127E-07 | 1.159E-06 | CYP2C9, CBR1, ALOX15, CYP2C19, PTGS1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 8.022E-08 | 9.626E-07 | CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.432E-07 | 1.289E-06 | CYP2C9, CYP1A2, ALDH1A1, CYP1A1, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 8.764E-06 | 6.310E-05 | CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 8.764E-06 | 6.310E-05 | FABP5, PPARG, PPARA, PPARD |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 5.939E-05 | 3.299E-04 | CYP2C9, ALOX15, CYP2C19, PTGS1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.166E-04 | 5.997E-04 | CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 5.956E-05 | 3.299E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 3.308E-04 | 1.588E-03 | CA2, CYP3A4, ABCG2 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 1.479E-03 | 6.262E-03 | GAA, AKR1B1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 8.672E-04 | 3.902E-03 | CA2, CA4 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 3.503E-05 | 2.293E-04 | CYP1A2, XDH |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | CBR1; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH; |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
